FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> Pfizer | Wyeth | Biogen Idec | ImClone | Amgen | Exubera

Pfizer kills off Exubera, hunts for deals

It's official: Pfizer is giving up on Exubera. Pulling its plug cost the company $2.8 billion against third-quarter earnings, a charge that sent profits tumbling 77 percent to $761 million. Once a blockbuster hopeful, the inhaled diabetes drug failed to catch on, delivering only $4 million in sales during the last quarter.

Meanwhile, analysts are still hashing over the company's next deal. A Citigroup report--based on conversations with Pfizer management--says the company will be "more transaction oriented" over the next year and a half. But rather than focusing on big buys, such as Amgen or Wyeth, the company probably will focus on smaller fry. Biogen Idec and its $23 billion market cap, for instance. The report recommends Biogen and ImClone as good fits.

- see this excerpt from Pfizer's release on Exubera
- see the full financial results
- check out this MSNBC report
- read the WSJ deal speculation

Related Articles:
Who should Pfizer buy? Report
Troubled Pfizer blueprints biotech venture effort. Report
Exubera becoming a big disappointment for Pfizer. Report
UK: Exubera not worth the price. Report
FDA approves Pfizer's inhaled insulin. Report

Read more on: Pfizer | Exubera | Diabetes | Biogen Idec | ImClone

Bookmark and Share
Get Your FREE FiercePharma Email Newsletter:
Be the first to comment
More stories about Pfizer   Wyeth   Biogen Idec   ImClone   Amgen   Exubera  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.